📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-29 16:43
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Vivanta Industries Approves Q1 FY27 Results; Announces Qness Pharma Collaboration
Vivanta Industries approved its unaudited financial results for the quarter ended June 30, 2026, during its board meeting on July 29, 2026. While specific Q1 figures were not detailed in the summary text, the company announced a new business collaboration with Qness Pharmaceuticals for manufacturing, branding, and marketing. This comes after a fiscal year (FY26) where the company achieved Rs 250 Cr in revenue but maintained a very thin PAT of Rs 1 Cr. The board also authorized opening a trading and demat account with Motilal Oswal, indicating active treasury or investment management.
Confidence: MEDIUM
What changedThe company has transitioned into the new financial year (FY27) and initiated a new business partnership in the pharmaceutical space.
Why it mattersFor a micro-cap company with a market cap of only Rs 19 Cr, the high revenue-to-market-cap ratio (over 13x) suggests the market is skeptical of its thin margins and low promoter skin-in-the-game. The new collaboration represents an attempt to diversify or strengthen its business model.
TTM Revenue: Rs 250 CrMarket Cap: Rs 19 CrDebt: Rs 18 CrPromoter Holding: 10.6%TTM Operating Profit Margin: -0.8%
📅 Short termThe stock may see limited movement until the specific profit/loss figures for the June quarter are parsed by the market, especially given the recent 12-month price decline of 40.6%.
📈 Long termThe company's ability to convert high revenue into meaningful bottom-line growth and improve its ROCE (currently 3.0%) is critical for long-term viability.
⚠ Risk flags
- Very low promoter holding (10.6%)
- High debt relative to market capitalization
- Historically thin/negative operating margins
- Micro-cap liquidity risks
Key Highlights
Approved standalone and consolidated financial results for the quarter ended June 30, 2026.
Executed a business collaboration agreement with Qness Pharmaceuticals for pharma product supply and marketing.
Company operates with a low promoter holding of 10.6% as of March 2026.
Reported TTM revenue of Rs 250 Cr against a small market capitalization of only Rs 19 Cr.
Debt levels remain significant at Rs 18 Cr, resulting in a Debt-to-Equity ratio of 1.00.
👀 What to Watch
Investors should examine the detailed Q1 FY27 financial tables to see if the negative operating margins (-0.8% TTM) have improved. Monitor for further disclosures regarding the financial terms and expected revenue contribution from the Qness Pharmaceuticals collaboration.
Vivanta Industries Approves Q1 FY27 Results and Announces Pharma Business Collaboration
Vivanta Industries approved its unaudited financial results for the quarter ended June 30, 2026, in a board meeting held on July 29, 2026. A key development is the board's note on a business collaboration agreement with Qness Pharmaceuticals for the manufacture, supply, and marketing of pharmaceutical products. The company also authorized opening a trading and demat account with Motilal Oswal Financial Services. Despite a high TTM revenue of ₹250 Cr, the company operates with a very small market cap of ₹19 Cr and thin margins.
Confidence: MEDIUM
What changedThe company has officially approved its Q1 FY27 results and entered into a new business collaboration in the pharmaceutical sector.
Why it mattersThe pharma collaboration represents a potential diversification or service expansion for a company primarily in civil construction. However, the extremely low promoter holding (10.6%) and high debt-to-equity (1.00) remain significant structural risks.
Market Capitalization: ₹19 CrTTM Revenue: ₹250 CrPromoter Holding: 10.6%Debt: ₹18 CrTTM Operating Profit Margin: -0.8%
📅 Short termThe stock may see volatility as the market reacts to the Q1 results and the new pharma collaboration, though the lack of specific deal values for the latter may limit immediate upside.
📈 Long termThe company's ability to scale the pharma collaboration and improve its razor-thin margins will be critical for long-term viability, especially given the low promoter skin-in-the-game.
⚠ Risk flags
- Very low promoter holding (10.6%)
- High debt relative to market cap (₹18 Cr debt vs ₹19 Cr M-Cap)
- Negative operating margins (-0.8% TTM)
- Lack of financial details regarding the Qness Pharmaceuticals agreement
Key Highlights
Approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026
Executed a business collaboration agreement with Qness Pharmaceuticals for branding and marketing of allied products
Authorized the opening of a Trading and Demat Account with Motilal Oswal Financial Services Limited (MOFSL)
Promoter holding remains low at 10.6% as per the latest March 2026 filings
Company reported a TTM revenue of ₹250 Cr against a market capitalization of only ₹19 Cr
👀 What to Watch
Investors should closely examine the full Q1 FY27 financial tables once published to see if margins have improved from the -0.8% TTM OPM. Monitor for further disclosures regarding the financial terms and expected revenue from the Qness Pharmaceuticals collaboration.
Vivanta Industries Board Meeting on July 24 to Approve Q1 Results and Pharma Collaboration
Vivanta Industries has scheduled a board meeting for July 24, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. Crucially, the board will also take note of a business collaboration agreement with Qness Pharmaceuticals for the manufacture, branding, and marketing of pharmaceutical products. This comes at a time when the company's TTM revenue stands at ₹250 Cr but with thin margins (OPM -0.8%) and a low promoter holding of 10.6%. Investors should watch for details on the pharma venture's scale relative to their existing civil construction business.
Confidence: HIGH
What changedThe company is formalizing a board review of its Q1 results and a new business collaboration with Qness Pharmaceuticals.
Why it mattersFor a micro-cap company (₹20 Cr) with declining quarterly revenues (from ₹75.89 Cr in June 2025 to ₹38.25 Cr in March 2026), a diversification into pharmaceuticals could be a significant strategic pivot to improve thin margins.
Market Capitalization: ₹20 CrTTM Revenue: ₹250 CrPromoter Holding: 10.6%Debt-to-Equity Ratio: 1.00Meeting Date: July 24, 2026
📅 Short termThe stock may see volatility leading up to the July 24 results and the disclosure of the pharma collaboration details.
📈 Long termThe structural significance depends on whether the pharma collaboration can reverse the trend of negative operating margins and declining revenue seen in the construction segment.
⚠ Risk flags
- Very low promoter holding (10.6%)
- Negative operating profit margin (-0.8%)
- High debt relative to market cap (₹18 Cr debt vs ₹20 Cr M-Cap)
Key Highlights
Board meeting scheduled for July 24, 2026, to approve Q1 FY27 financial results.
Agenda includes noting a business collaboration with Qness Pharmaceuticals for pharma and allied products.
Authorization of signatories for the financial statements of the year ended March 31, 2026.
Company reports a low promoter holding of 10.6% as of March 2026.
TTM revenue of ₹250 Cr contrasts with a small market capitalization of only ₹20 Cr.
👀 What to Watch
Monitor the July 24 board meeting outcome for specific financial terms of the Qness Pharmaceuticals collaboration and any shift in business strategy from civil construction to pharma.
